Naltrexone IBS Studies Show Superior Risk Profile Vs. Lotronex, Zelnorm, Pain Therapeutics Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pain Therapeutics is conducting two Phase III studies for the opioid antagonist in men and women with chronic IBS. The next IBS agent on the market, however, is likely to be Solvay's Calmactin.